Details for Patent: 7,153,845

Title:	Bioadhesive progressive hydration tablets
Abstract:	A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
Inventor(s):	Levine; Howard L. (Oceanside, NY), Bologna; William J. (Paris, FR), Cartier; Philippe J. (Paris, FR), De Ziegler; Dominique (Geneva, CH)
Assignee:	Columbia Laboratories, Inc. (Livingston, NJ)
Filing Date:	Apr 24, 2003
Application Number:	10/421,840
Claims:	1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition for delivering an active ingredient to a mucosal surface of a mammal, comprising: an effective amount of an active ingredient, a water insoluble, water-swellable cross-linked polycarboxylic polymer, which is polycarbophil and a water soluble polymer, wherein the active ingredient comprises desmopressin or prostaglandin E2 and the polymers are present in an amount in combination which enables the composition to become progressively hydrated to provide an extended release of the active ingredient over time. 2. The composition of claim 1, wherein the active ingredient is desmopressin and is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition, and the composition is formulated to deliver the desmopressin via the buccal cavity and the tablet gelifies or swells to avoid asphyxiation. 3. The composition of claim 1, wherein the active ingredient is prostaglandin E2 and is present in an amount of up to about 2 mg per unit dosage of the composition. 4. The composition of claim 3, wherein the amount of prostaglandin E2 is in an amount of up to about 0.5 mg per unit dosage of the composition. 5. The composition of claim 1, wherein the composition is formulated as a tablet for delivery of the active ingredient via the buccal, vaginal, nasal, or rectal cavity. 6. The composition of claim 1, wherein the water insoluble. water-swellable cross-linked polycarboxylic polymer is polycarbophil. 7. The composition of claim 1, wherein the tablet is formulated to gelify or swell to avoid asphyxiation. 8. The composition of claim 1, wherein said water soluble polymer is carbomer 974P. 9. The composition of claim 1, wherein the composition delivers active ingredients for at least 48 hours. 10. The composition of claim 1, wherein the composition delivers active ingredients for as much as 72 hours. 11. A method of delivering an active ingredient to a mucosal surface of a mammal, which comprises associating the active ingredient in a composition with a water insoluable, water-swellable cross-linked polycarboxylic polymer which is polycarbophil and a water soluble polymer, so that when the composition is administered to the mammal, the composition becomes progressively hydrated to provide an extended release of the active ingredient, wherein the active ingredient comprises desmopressin or prostaglandin E2. 12. The method of claim 11, wherein the active ingredient is prostaglandin E2 and is present in an amount of up to about 2 mg per unit dosage of composition. 13. The method of claim 12, wherein the amount of prostaglandin E2 is up to about 0.5 mg per unit dosage of the composition. 14. The method of claim 11, wherein the active ingredient is desmopressin and is present in an amount of about 0.025 mg to 0.2 mg per unit dosage of the composition and said composition is formulated for delivery via the buccal cavity.